Skip to main content

“Life Technologies Corp. et al. v. Promega Corp.”

Decision of the Supreme Court of the United States 22 February 2017 – Case No. 14–1538

  1. 1.

    The supply of a single component of a multicomponent invention for manufacture abroad does not give rise to the liability derived from §271(f)(1) of the Patent Act, which prohibits the supply from the United States of all or a substantial portion of the components of a patented invention.

  2. 2.

    Section 271(f)(1)’s phrase “substantial portion” refers to a quantitative measurement. Nothing in the neighboring text points to a qualitative interpretation, which would render the modifying phrase “of the components” unnecessary the first time it is used in §271(f)(1).

  3. 3.

    Under a quantitative approach, a single component cannot constitute a “substantial portion”. Section 271(f)(1) consistently refers to the plural “components,” indicating that multiple components make up the substantial portion. A different interpretation would undermine §271(f)(2)’s express reference to a single component “especially made or especially adapted for use in the invention.”

Author information

Consortia

Additional information

Available at https://www.supremecourt.gov/.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Life Technologies Corp. et al. v. Promega Corp. Patent Act, §271(f)(1). “Life Technologies Corp. et al. v. Promega Corp.”. IIC 48, 588 (2017). https://doi.org/10.1007/s40319-017-0610-1

Download citation

Keywords

  • Multicomponent invention
  • Single component
  • Substantial portion
  • Quantitative interpretation
  • Supply of components
  • Qualitative interpretation